Literature DB >> 23859917

The legal aspects of expedited partner therapy practice: do state laws and policies really matter?

Ryan Cramer1, Jami S Leichliter, Mark R Stenger, Penny S Loosier, Lauren Slive.   

Abstract

BACKGROUND: Expedited partner therapy (EPT) is a potential partner treatment strategy. Significant efforts have been devoted to policies intended to facilitate its practice. However, few studies have attempted to evaluate these policies.
METHODS: We used data on interviewed gonorrhea cases from 12 sites in the STD Surveillance Network in 2010 (n = 3404). Patients reported whether they had received EPT. We coded state laws relevant to EPT for gonorrhea using Westlaw legal research database and the general legal status of EPT in STD Surveillance Network sites from Centers for Disease Control and Prevention's Web site in 2010. We also coded policy statements by medical and other boards. We used χ tests to compare receipt of EPT by legal/policy variables, patient characteristics, and provider type. Variables significant at P < 0.10 in bivariate analyses were included in a logistic regression model.
RESULTS: Overall, 9.5% of 2564 interviewed patients with gonorrhea reported receiving EPT for their partners. Receipt of EPT was significantly higher where laws and policies authorizing EPT existed. Where EPT laws for gonorrhea existed and EPT was permissible, 13.3% of patients reported receiving EPT as compared with 5.4% where there were no EPT laws and EPT was permissible, and 1.0% where there were no EPT laws and EPT was potentially allowable (P < 0.01). Expedited partner therapy was higher where professional boards had policy statements supporting EPT (P < 0.01). Receipt of EPT did not differ by most patient characteristics or provider type. Policy-related findings were similar in adjusted analyses.
CONCLUSIONS: Expedited partner therapy laws and policies were associated with higher reports of receipt of EPT among interviewed gonorrhea cases.

Entities:  

Mesh:

Year:  2013        PMID: 23859917      PMCID: PMC3927721          DOI: 10.1097/01.OLQ.0000431358.18959.d4

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  10 in total

1.  Chlamydia partner services for females in California family planning clinics.

Authors:  Ying-Ying Yu; Jessica A Frasure-Williams; Eileen F Dunne; Gail Bolan; Lauri Markowitz; Heidi M Bauer
Journal:  Sex Transm Dis       Date:  2011-10       Impact factor: 2.830

2.  Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.

Authors:  Matthew R Golden; William L H Whittington; H Hunter Handsfield; James P Hughes; Walter E Stamm; Matthew Hogben; Agnes Clark; Cheryl Malinski; Jennifer R L Helmers; Katherine K Thomas; King K Holmes
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

3.  Patient-delivered partner treatment for male urethritis: a randomized, controlled trial.

Authors:  Patricia Kissinger; Hamish Mohammed; Gwangi Richardson-Alston; Jami S Leichliter; Stephanie N Taylor; David H Martin; Thomas A Farley
Journal:  Clin Infect Dis       Date:  2005-07-19       Impact factor: 9.079

4.  Patient-delivered partner therapy for chlamydial infections: practices, attitudes, and knowledge of california family planning providers.

Authors:  Sharon Jotblad; Ina U Park; Heidi M Bauer; Aileen Barandas; Melanie Deal; Annette Amey
Journal:  Sex Transm Dis       Date:  2012-02       Impact factor: 2.830

5.  Reticence to prescribe: utilization of expedited partner therapy among obstetrics providers in Arizona.

Authors:  M M Taylor; M G Collier; M M Winscott; T Mickey; B England
Journal:  Int J STD AIDS       Date:  2011-07-08       Impact factor: 1.359

6.  Implementation and effectiveness of an expedited partner therapy program in an urban clinic.

Authors:  Theresa Mickiewicz; Alia Al-Tayyib; Mark Thrun; Cornelis Rietmeijer
Journal:  Sex Transm Dis       Date:  2012-12       Impact factor: 2.830

7.  The cost and cost-effectiveness of expedited partner therapy compared with standard partner referral for the treatment of chlamydia or gonorrhea.

Authors:  Thomas L Gift; Patricia Kissinger; Hamish Mohammed; Jami S Leichliter; Matthew Hogben; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2011-11       Impact factor: 2.830

Review 8.  Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review.

Authors:  Sven Trelle; Aijing Shang; Linda Nartey; Jackie A Cassell; Nicola Low
Journal:  BMJ       Date:  2007-02-17

9.  Expedited partner therapy for sexually transmitted diseases: assessing the legal environment.

Authors:  James G Hodge; Amy Pulver; Matthew Hogben; Dhrubajyoti Bhattacharya; Erin Fuse Brown
Journal:  Am J Public Health       Date:  2008-01-02       Impact factor: 9.308

10.  Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial.

Authors:  Julia A Schillinger; Patricia Kissinger; Helene Calvet; William L H Whittington; Ray L Ransom; Maya R Sternberg; Stuart M Berman; Charlotte K Kent; David H Martin; M Kim Oh; H Hunter Handsfield; Gail Bolan; Lauri E Markowitz; J Dennis Fortenberry
Journal:  Sex Transm Dis       Date:  2003-01       Impact factor: 2.830

  10 in total
  13 in total

1.  State-level gonorrhea rates and expedited partner therapy laws: insights from time series analyses.

Authors:  K Owusu-Edusei; R Cramer; H W Chesson; T L Gift; J S Leichliter
Journal:  Public Health       Date:  2017-03-24       Impact factor: 2.427

2.  A Scan of CDC-Authored Articles on Legal Epidemiology, 2011-2015.

Authors:  Leila Martini; David Presley; Sarah Klieger; Scott Burris
Journal:  Public Health Rep       Date:  2016-10-19       Impact factor: 2.792

3.  Physician Adherence to Centers for Disease Control and Prevention Guidelines for Sexually Active Adolescents in the Pediatric Emergency Setting.

Authors:  Michelle L Pickett; Marlene D Melzer-Lange; Melissa K Miller; Seema Menon; Alexis M Vistocky; Amy L Drendel
Journal:  Pediatr Emerg Care       Date:  2018-11       Impact factor: 1.454

4.  Use of Patient-Delivered Partner Therapy in US College Settings: Associations With Legality, Perceived Legality and Other Sexual and Reproductive Health Services.

Authors:  Matthew Hogben; Alexandra Caccamo; Oscar Beltran; Ryan Cramer; Melissa A Habel
Journal:  Sex Transm Dis       Date:  2017-11       Impact factor: 2.830

5.  Epidemiological Impact of Expedited Partner Therapy for Men Who Have Sex With Men: A Modeling Study.

Authors:  Kevin M Weiss; Jeb S Jones; David A Katz; Thomas L Gift; Kyle Bernstein; Kimberly Workowski; Eli S Rosenberg; Samuel M Jenness
Journal:  Sex Transm Dis       Date:  2019-11       Impact factor: 2.830

6.  Expedited partner therapy for sexually transmitted diseases--are we there yet?

Authors:  Patricia J Kissinger
Journal:  Sex Transm Dis       Date:  2014-11       Impact factor: 2.830

7.  Community-Based Assessment to Inform a Chlamydia Screening Program for Women in a Rural American Indian Community.

Authors:  Lucy Smartlowit-Briggs; Cynthia Pearson; Patricia Whitefoot; Bianca N Altamirano; Michelle Womack; Marie Bastin; Julia C Dombrowski
Journal:  Sex Transm Dis       Date:  2016-06       Impact factor: 2.830

Review 8.  Sexually Transmitted Disease Prevention Policies in the United States: Evidence and Opportunities.

Authors:  Jami S Leichliter; Naomi Seiler; Dan Wohlfeiler
Journal:  Sex Transm Dis       Date:  2016-02       Impact factor: 2.830

9.  Assessment: A Core Function for Implementing Effective Interventions in Sexually Transmitted Disease Control Programs.

Authors:  Karen Kroeger; Elizabeth Torrone; Robert Nelson
Journal:  Sex Transm Dis       Date:  2016-02       Impact factor: 2.830

10.  Use of Expedited Partner Therapy for Sexually Transmitted Diseases in College and University Health Centers in the United States, 2011-2012.

Authors:  Ryan Cramer; Nina Martinez; Craig Roberts; Melissa A Habel; E Victor Leino; Jami S Leichliter
Journal:  Sex Transm Dis       Date:  2015-10       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.